147 related articles for article (PubMed ID: 24582211)
21. Chemo-immunotherapy improves long-term survival in a preclinical model of MMR-D-related cancer.
Maletzki C; Wiegele L; Nassar I; Stenzel J; Junghanss C
J Immunother Cancer; 2019 Jan; 7(1):8. PubMed ID: 30630527
[TBL] [Abstract][Full Text] [Related]
22. Gemcitabine nanoparticles promote antitumor immunity against melanoma.
Zhang Y; Bush X; Yan B; Chen JA
Biomaterials; 2019 Jan; 189():48-59. PubMed ID: 30388589
[TBL] [Abstract][Full Text] [Related]
23. Dual depletion of myeloid-derived suppressor cells and tumor cells with self-assembled gemcitabine-celecoxib nano-twin drug for cancer chemoimmunotherapy.
Zhang X; Liang Q; Cao Y; Yang T; An M; Liu Z; Yang J; Liu Y
J Nanobiotechnology; 2024 Jun; 22(1):319. PubMed ID: 38849938
[TBL] [Abstract][Full Text] [Related]
24. Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas.
Plate JM; Plate AE; Shott S; Bograd S; Harris JE
Cancer Immunol Immunother; 2005 Sep; 54(9):915-25. PubMed ID: 15782312
[TBL] [Abstract][Full Text] [Related]
25. Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors.
Dhar D; Raina K; Kumar D; Wempe MF; Bagby SM; Pitts TM; Orlicky DJ; Agarwal C; Messersmith WA; Agarwal R
Mol Carcinog; 2020 Oct; 59(10):1227-1240. PubMed ID: 32816368
[TBL] [Abstract][Full Text] [Related]
26. Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway.
Zhang J; Xu HX; Cho WCS; Cheuk W; Li Y; Huang QH; Yang W; Xian YF; Lin ZX
J Exp Clin Cancer Res; 2022 Mar; 41(1):90. PubMed ID: 35272669
[TBL] [Abstract][Full Text] [Related]
27. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.
Réjiba S; Reddy LH; Bigand C; Parmentier C; Couvreur P; Hajri A
Nanomedicine; 2011 Dec; 7(6):841-9. PubMed ID: 21419876
[TBL] [Abstract][Full Text] [Related]
28. Progression of Large Lymphoma Is Significantly Impeded with a Combination of Gemcitabine Chemotherapy and Dendritic Cells Intra-Tumor Vaccination.
Zhu XJ; Yang ZF; Zhou JY; Liu L; Sun XM; Fan ZF; Hu SY; Chen YC; Li WX; Cao M; Wang LX
PLoS One; 2015; 10(7):e0132799. PubMed ID: 26181041
[TBL] [Abstract][Full Text] [Related]
29. A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models.
Matsumoto T; Komori T; Yoshino Y; Ioroi T; Kitahashi T; Kitahara H; Ono K; Higuchi T; Sakabe M; Kori H; Kano M; Hori R; Kato Y; Hagiwara S
Pharm Res; 2021 Jun; 38(6):1093-1106. PubMed ID: 33961188
[TBL] [Abstract][Full Text] [Related]
30. Hexokinase 2 dimerization and interaction with voltage-dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cancer.
Fan K; Fan Z; Cheng H; Huang Q; Yang C; Jin K; Luo G; Yu X; Liu C
Cancer Med; 2019 Oct; 8(13):5903-5915. PubMed ID: 31426130
[TBL] [Abstract][Full Text] [Related]
31. Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression.
Guo Z; Wang F; Di Y; Yao L; Yu X; Fu D; Li J; Jin C
Int J Nanomedicine; 2018; 13():4869-4880. PubMed ID: 30214194
[TBL] [Abstract][Full Text] [Related]
32. EGFR-Targeted Polymeric Mixed Micelles Carrying Gemcitabine for Treating Pancreatic Cancer.
Mondal G; Kumar V; Shukla SK; Singh PK; Mahato RI
Biomacromolecules; 2016 Jan; 17(1):301-13. PubMed ID: 26626700
[TBL] [Abstract][Full Text] [Related]
33. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.
Suzuki E; Kapoor V; Jassar AS; Kaiser LR; Albelda SM
Clin Cancer Res; 2005 Sep; 11(18):6713-21. PubMed ID: 16166452
[TBL] [Abstract][Full Text] [Related]
34.
Yang H; Tong Z; Shen L; Sun YU; Hoffman RM; Huang J
Anticancer Res; 2020 Sep; 40(9):4969-4978. PubMed ID: 32878785
[TBL] [Abstract][Full Text] [Related]
35. Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma.
Ohtaka K; Kohya N; Sato K; Kitajima Y; Ide T; Mitsuno M; Miyazaki K
Oncol Rep; 2008 Aug; 20(2):279-86. PubMed ID: 18636187
[TBL] [Abstract][Full Text] [Related]
36. Interferon-alpha modulates the chemosensitivity of CD133-expressing pancreatic cancer cells to gemcitabine.
Hayashi T; Ding Q; Kuwahata T; Maeda K; Miyazaki Y; Matsubara S; Obara T; Natsugoe S; Takao S
Cancer Sci; 2012 May; 103(5):889-96. PubMed ID: 22320450
[TBL] [Abstract][Full Text] [Related]
37. Gemcitabine has significant immunomodulatory activity in murine tumor models independent of its cytotoxic effects.
Suzuki E; Sun J; Kapoor V; Jassar AS; Albelda SM
Cancer Biol Ther; 2007 Jun; 6(6):880-5. PubMed ID: 17582217
[TBL] [Abstract][Full Text] [Related]
38. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity.
Vincent J; Mignot G; Chalmin F; Ladoire S; Bruchard M; Chevriaux A; Martin F; Apetoh L; Rébé C; Ghiringhelli F
Cancer Res; 2010 Apr; 70(8):3052-61. PubMed ID: 20388795
[TBL] [Abstract][Full Text] [Related]
39. Gemcitabine and checkpoint blockade exhibit synergistic anti-tumor effects in a model of murine lung carcinoma.
Du B; Wen X; Wang Y; Lin M; Lai J
Int Immunopharmacol; 2020 Sep; 86():106694. PubMed ID: 32570034
[TBL] [Abstract][Full Text] [Related]
40. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
Horiuchi T; Uwagawa T; Shirai Y; Saito N; Iwase R; Haruki K; Shiba H; Ohashi T; Yanaga K
J Surg Res; 2016 Nov; 206(1):1-8. PubMed ID: 27916347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
